Physician profile
Yan Li
NPI 1508803792
$3,404.53
in general payments reported to CMS, 2019-2025
15 companies · $876 in 2025
The $876 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $88.08 · 2021: $124 · 2022: $375 · 2023: $872 · 2024: $818 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,566.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,031.16 | 2020-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $365.11 | 2023-2025 | Dupixent |
| Astrazeneca Pharmaceuticals Lp | $270.75 | 2023-2025 | Farxiga, Breztri |
| Gilead Sciences, INC. | $243.50 | 2023 | Vemlidy, Epclusa |
| Glaxosmithkline, LLC. | $235.34 | 2024-2025 | Nucala |
| Stryker Corporation | $166.67 | 2023 | Mako |
| Bayer Healthcare Pharmaceuticals INC. | $150.00 | 2025 | |
| Genzyme Corporation | $142.59 | 2022 | |
| Travere Therapeutics, INC. | $135.71 | 2024 | |
| Madrigal Pharmaceuticals | $131.58 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Horizon Therapeutics Plc | $125.00 | 2019 | |
| Exact Sciences Corporation | $120.83 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $105.05 | 2024-2025 | Verquvo |
| Lilly USA, LLC | $56.24 | 2020-2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.